Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04126187 · ClinicalTrials.gov registry record
AcrySof® Bilateral PanOptix(R) Spectacle Freedom and Patient Satisfaction Study
A clinical trial, sponsored by Gainesville Eye Associates.
- Completed
- Registry status
- 30
- Enrollment target
NCT04126187: Completed study, sponsored by Gainesville Eye Associates.
NCT04126187 is a clinical trial that has completed, run by Gainesville Eye Associates. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04126187 has completed, sponsored by Gainesville Eye Associates.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The objective of this study is to assess the spectacle independence of patients receiving the AcrySof® Panoptix® Intraocular lens (IOL) after uneventful cataract surgery.
Primary Outcome
Percent of patients who never or rarely wear spectacles for distance, intermediate or near vision 3 months postop (based on the Patient-Reported Spectacle Independence Questionnaire (PRSIQ) - "a little of the time" or "none of the time")
Interventions
- DEVICE Panoptix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-05-14 |
| Est. Completion | 2021-03-30 |
What the finished NCT04126187 record still lists
NCT04126187 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Panoptix is the first listed.
NCT04126187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04126187 about?
NCT04126187 is a clinical study titled "AcrySof® Bilateral PanOptix(R) Spectacle Freedom and Patient Satisfaction Study". The objective of this study is to assess the spectacle independence of patients receiving the AcrySof® Panoptix® Intraocular lens (IOL) after uneventful cataract surgery.
What is the current status of trial NCT04126187?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2020-05-14. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT04126187?
The interventions under investigation include: Panoptix (DEVICE).
Who is sponsoring clinical trial NCT04126187?
This trial is sponsored by Gainesville Eye Associates, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI